​

Funding Round

Series B - Xilio Therapeutics

Series B - Xilio Therapeutics

Investment Firm

Overview

Xilio Therapeutics is a biotechnology company that develops tumor-activated immuno-oncology therapies.

Announced Date

Mar 02, 2020

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Takeda Ventures

Takeda Ventures

Takeda Ventures is a early_stage_venture and late_stage_venture firm.

Participant Investors

10

Investor Name
Participant InvestorRiverVest
Participant InvestorF-Prime Capital
Participant InvestorBay City Capital
Participant InvestorAtlas Venture
Participant InvestorSV Health Investors

Round Details and Background

Xilio Therapeutics raised $100500000 on 2020-03-02 in Series B

Xilio Therapeutics is a biotechnology company that develops tumor-activated immuno-oncology therapies.

Company Funding History

5

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Mar 02, 2020
Series B - Xilio Therapeutics
10-100.5M
Feb 24, 2021
Series C - Xilio Therapeutics
9-95.0M
Mar 28, 2024
Post-IPO Equity - Xilio Therapeutics
2-11.3M
Oct 12, 2016
Series A - Xilio Therapeutics
1-7.5M

Recent Activity

There is no recent news or activity for this profile.